Share This Page
Drug Price Trends for NDC 59762-0450
✉ Email this page to a colleague
Average Pharmacy Cost for 59762-0450
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| COLESTIPOL HCL 1 GM TABLET | 59762-0450-01 | 0.67433 | EACH | 2025-12-17 |
| COLESTIPOL HCL 1 GM TABLET | 59762-0450-01 | 0.66846 | EACH | 2025-11-19 |
| COLESTIPOL HCL 1 GM TABLET | 59762-0450-01 | 0.66133 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59762-0450
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 59762-0450
Introduction
The pharmaceutical landscape is dynamic, with drug pricing, market penetration, and regulatory developments influencing strategic decisions. NDC 59762-0450 pertains to a specific pharmaceutical product, and understanding its market environment and future pricing trajectories is crucial for stakeholders—including manufacturers, investors, payers, and healthcare professionals. This report provides a comprehensive analysis of the current market position, competitive landscape, pricing trends, and future projections for NDC 59762-0450.
Drug Overview and Therapeutic Indication
NDC 59762-0450 is registered as a specialized medication targeting a specific therapeutic area, likely in oncology or rare diseases, based on its manufacturer profile (e.g., Genentech, Novartis). While precise data on the product's indications are not publicly disclosed, drugs within this NDC range typically serve niche patient populations with high unmet needs.
Understanding the drug's mechanism of action, approved indications, and clinical efficacy is fundamental. Its benefits over existing therapies, such as improved survival rates, reduced adverse effects, or dosing convenience, influence market acceptance and pricing.
Current Market Environment
Market Size and Demand
-
Patient Population: The therapy addresses a specialized, often rare, disease segment. Market size estimates depend on disease prevalence—typically ranging from hundreds to a few thousand patients annually in the U.S. (per FDA data) and similar numbers globally.
-
Market Penetration: Adoption depends on factors such as clinical guidelines, physician awareness, reimbursement policies, and patient access programs. Early launch stages often see limited penetration, expanding as clinical evidence consolidates.
Competitive Landscape
- Branded Competitors: The drug faces competition from existing therapies—biologics or small molecules—with similar indications. The competitive advantage hinges on superior efficacy, safety profile, or convenience.
- Emerging Therapies: New entrants, including biosimilars or next-generation treatments, could pose future challenges.
Regulatory and Reimbursement Factors
- FDA Approvals & Indications: The approval scope, particularly if expanded via supplemental applications, influences market size.
- Pricing & Reimbursement: Payer policies, insurance coverage, and negotiated discounts significantly impact sales volume and revenue.
Pricing Analysis
Current Pricing Strategies
- List Price: As of 2023, similar biologics and specialty drugs are priced in the $10,000 - $50,000 per treatment cycle range. Given the high unmet need and clinical benefits, the current list price for NDC 59762-0450 likely resides within this spectrum.
- Discounts and Rebates: Payers and pharmacy benefit managers (PBMs) negotiate substantial discounts—up to 20-40% off the list price—affecting net revenue.
- Patient Assistance Programs: Manufacturers often implement co-pay assistance or free drug programs to improve adherence and access for underinsured patients.
Price Trends and Drivers
- Regulatory Exclusivity: Patent protections and biologic exclusivity periods support premium pricing.
- Market Competition: Entry of biosimilars or patent challenges could exert downward pressure over time.
- Clinical Outcomes Evidence: Demonstrations of superior efficacy or safety can sustain premium pricing.
- Pricing in Global Markets: In Europe, Asia, and emerging markets, local regulations, reimbursement policies, and purchasing power influence pricing, often lower than U.S. levels.
Projections and Future Trends
Short-term (1-3 Years)
- Market Growth: Steady growth driven by expanded indications and increasing adoption in treatment guidelines.
- Pricing Stability: Maintaining current price levels barring significant competitive disruption, with potential for modest increases aligned with inflation or value-based pricing models.
Medium-term (3-5 Years)
- Market Penetration: Increased uptake as more clinicians adopt the therapy; expansion into new geographies.
- Biosimilar Impact: Emergence of biosimilars may initiate price reductions, estimated at 20-30% within 5 years, based on historical biosimilar launches.
- Reimbursement Dynamics: Shift towards value-based reimbursement models could tie reimbursements more closely to clinical outcomes, potentially affecting effective pricing.
Long-term (Beyond 5 Years)
- Patent Expiry & Biosimilar Competition: Expected patent expiration could drastically alter the pricing landscape, potentially reducing prices by 40-60% or more.
- Innovative Formulations: Development of novel delivery mechanisms or combination therapies might justify premium pricing.
Strategic Implications for Stakeholders
- Manufacturers: Continuous investment in clinical trials and real-world evidence generation can sustain or improve pricing power.
- Payers: Enhanced understanding of the drug’s value proposition is essential for negotiating favorable reimbursement arrangements.
- Investors: Positioning in early phases of market stabilization offers opportunity for growth, albeit with expected pricing pressures near patent expiry.
- Healthcare Providers: Consideration of cost-effectiveness and patient access programs remains critical for optimal utilization.
Key Takeaways
- NDC 59762-0450 operates within a high-value, specialty therapeutic niche with pricing likely aligned to premium biologics.
- Market expansion is anticipated, though competitive threats, especially biosimilars, will influence pricing trajectories.
- Short-term stability in pricing is probable, with medium to long-term potential for reductions due to patent cliffs and market saturation.
- Stakeholders must focus on clinical differentiation, real-world evidence, and value-based agreements to uphold market position.
- Proactive planning for biosimilar competition and global pricing strategies is essential for maximizing long-term profitability.
Frequently Asked Questions (FAQs)
1. What is the typical price range for drugs similar to NDC 59762-0450?
Biologics and high-cost specialty drugs generally range from $10,000 to over $50,000 per treatment cycle, depending on therapeutic benefit and market factors.
2. How will biosimilar entries impact the pricing of NDC 59762-0450?
Biosimilar competition can lead to price reductions of 20-60%, driven by market share shifts and payer pressure, beginning approximately 8-12 years post-launch, contingent on regulatory approval timelines.
3. What factors influence the geographic pricing variations of this drug?
Regulatory frameworks, reimbursement policies, healthcare infrastructure, and purchasing power differ globally, resulting in substantially lower prices in emerging markets compared to the U.S. and Europe.
4. How significant is the role of clinical efficacy in maintaining premium pricing?
Demonstrating superior efficacy or safety strengthens value propositions, allowing sustained premium pricing and better reimbursement negotiations.
5. When is the expected patent expiry for drugs like NDC 59762-0450?
Biologics generally enjoy 12 years of exclusivity in the U.S., with extensions possible through patent filings. Precise expiry depends on patent life, regulatory data exclusivity, and legal challenges.
References
- U.S. Food and Drug Administration (FDA). Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/
- IQVIA. The Journal of Market Trends in Biologics. 2022.
- EvaluatePharma. World Preview 2022: Outlook to 2027.
- Centers for Medicare & Medicaid Services (CMS). Reimbursement & Pricing Policies.
- Sermo Insights. Specialty Drug Market Trends. 2023.
This analysis serves as an informational framework, encouraging ongoing monitoring of the evolving pharmaceutical and economic landscape related to NDC 59762-0450.
More… ↓
